Day One: Wednesday April 24, 2019

REGISTRATION & COFFEE

8:00

Introduction and Summary

8:15

Novel Antibody Constructs for Breast Cancer

8:30

Arming antibodies for the fight against cancer

Alex Lazar
Director, Analytical & Pharmaceutical Sciences

 

ImmunoGen

9:00

Discovery of Novel Linker Payloads and Antibody Drug Conjugates for the Treatment of Cancer

Omar Ahmad
Principal Scientist, Group Leader

 

Pfizer

9:30

Sacituzumab Govitecan: Scientific rationale and clinical development in breast cancer

Robert Iannone

Head of Research and Development and CMO

 

Immunomedics

10:00

CONJUGATION AND FILL fiNISH - HOW TO SECURE THE SUPPLY CHAIN OF ADCs

 

Giorgio Salciarini

Technical Business Development Manager

 

BSP Pharmaceuticals

MORNING REFRESHMENTS & SPEED NETWORKING

10:30

11:30

ZW49: Combining the Azymetric and ZymeLink platforms to expand the therapeutic window of a bispecific HER2-targeting ADC



Rupert Davies

Principal Scientist, Oncology

 

Zymeworks

Immunotherapy in Breast Cancer

12:00

Immunotherapy in Breast Cancer: Moving forward

 

Dimitrios Zardavas

Program Lead, Breast Cancer

Bristol Myers Squibb

12:30

Transforming Translational Research: CANscriptâ„¢ - A Better Predictive Model For Oncology

Stefan Jellbauer

Technical Liaison, Biopharma Business Development

 

Mitra Biotech

LUNCH & NETWORKING

1:00

2:00

PD-1 inhibition for breast cancer treatment

 

 

Vassiliki Karantza

Senior Director, Clinical Research Oncology

 

Merck

2:30

Development of combination immunotherapy for breast cancer

 

 

Sarah Wang

Principal Scientist, Translational R&D

 

TESARO

3:00

Local regulated IL-12 productions impact on the treatment of breast cancer. Bench to bedside

 

John Barrett

VP R&D

 

Ziopharm

AFTERNOON REFRESHMENTS & NETWORKING

3:30

4:00

Can Cancer Immunotherapy be both Personalized and Off-the-Shelf?

 

William Williams

Chief Executive Officer

Briacell

4:30

Progressing our mechanistic understanding of anti-CTLA-4 therapy: next generation anti-CTLA-4 antibodies for cancer immunotherapy

 

Dhan Chand

Senior Scientist

 

Agenus

5:00

The  developing treatment for triple negative breast cancer utilizing a multi-functional immunotherapeutic platform


Mahesh Narayanan

CEO

PepVax

DRINKS RECEPTION & NETWORKING

5:30

VIEW NEXT DAY

DOWNLOAD EVENT GUIDE

Complete the form below to download the PDF

NEO SYNTH International House, 24 Holborn Viaduct, London EC1A 2BN

contact@neo-synth.com

(+1) 617.500.5172

Submitting Form...

The server encountered an error.

Request received. Please allow some time for processing - You will receive a manual response within a few hours.

Your details will not be shared with a third party

Copyright © 2016 | All content produced by: neo-synth ltd.

Registration

Speed Networking

Lunch

Immunotherapy

Coffee Break

End of Day 1

DOWNLOAD GUIDE